Vericiguat is a potent guanylate cyclase stimulant under the development of Bayer HealthCare Pharmaceuticals. Direct stimulation of guanylate cyclase is emerging as a potential new approach for the treatment of renal disorders. In Aug 2016, Bayer in collaboration with Merck completed phase-I clinical trials in Coronary artery disease (In adults, In the elderly) in Germany. In Sep 2016, Phase-III clinical trials in Chronic heart failure in Germany, Hungary and Spain was on-going.